News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aduro Biotech Licenses GVAX Pancreas from BioSante Pharmaceuticals, Inc. (BPAX) to Develop a Therapeutic Vaccine in Conjunction with CRS-207 for Pancreatic Cancer



4/18/2011 10:39:54 AM

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine (GVAX Pancreas) and GVAX Prostate Cancer Vaccine (GVAX Prostate) from BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) in exchange for milestone and royalty payments after commercialization. Aduro also has an option to additional GVAX cancer vaccine indications, all for use in combination with the company’s proprietary vaccine platform based on Listeria monocytogenes (Lm). Aduro initially plans to develop a novel sequential vaccine regimen for the treatment of pancreatic cancer using GVAX Pancreas and CRS-207.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES